The Significance Of Flow Cytometry Detect Minimal Residual Disease In The New Diagnosis Of Multiple Myeloma

Research purposes:Flow cytometry(FCM)was used to detect minimal residual disease in newly diagnosed multiple myeloma after 2 period of treatments,and after 4periodoftreatments,comparingbortezomib-basedchemotherapy withbortezomib-free.Therapeutic effect of chemotherapy regimen,and analysis of the significance of minimal residual disease(MRD)in and after treatment,to evaluate its relationship with treatment options and survival prognosis,and then to analyze MRD for disease diagnosis,predict recurrence and early intervention.The clinical significance of the aspect,thereby further guiding the design of the treatment plan and evaluating the efficacy.Research method:1.A retrospective analysis of 56 patients with multiple myeloma who were newly diagnosed from January 2016 to December 2018 was performed.The follow-up date was May 31,2019,and the treatment effect and prognosis were evaluated.2.Eight-color flow cytometry(CD38/CDl38/CDl9/CD45 or CD38/CDl38)was used for the MRD of 56 patients with multiple myeloma who were newly diagnosed in our department of hematology before treatment,2 courses of treatment,and 4 courses of treatment./CD56/CD45)for testing.According to the MRD test results,the two groups were divided into low MRD and high MRD.Among them,the low MRD group(MRD<10e-3),the high MRD group(MRD?10e-3),the MRD negative standard was MRD<10e-4,and the MRD negative was attributed to the low MRD group.3.Analytical data:Statistical analysis was performed using SPSS 22.0 software.Quantitative data of normal distribution were expressed as mean±standard deviation,and t-test was used for comparison between groups.The non-normal distribution quantitative data were expressed as median(P25,P75),and two independent samples were used for comparison between groups.Nonparametric test;qualitative data is expressed in frequency,and?~2 test is used for comparison between groups.P<0.05was considered statistically significant.Research result:1,through analysis can be concluded:platelets,blood?2microglobulin,serum calcium concentration,albumin,etc.affect the prognosis of patients.2.As the course of treatment increases,the rate of low MRD increases.3,the relationship between treatment and curative effect:4 courses of effective rate of82.09%,2 courses of effective rate of 72.03%,effective rate of X2=6.000,P=0.014,the difference is statistically significant,which can be concluded with the increase in the course of treatment,the patient's efficiency It is higher than before.4.Relationship between course of treatment and low MRD rate:After 2 courses of treatment,14patients in low MRD group,40 patients in high MRD group,low MRD rate:20.59%,after 4 courses of treatment,21 persons in low MRD group and33persons in high MRD group,low The MRD rate was 38.64%,the effective rate was X2=6.000,P=0.014,and the difference was statistically significant(P<0.05).From the comparison of the two groups of results,it was found that the 4 courses were more effective than the 2 courses,and there was a statistically significant difference between the two groups(P<0.05).5,CR rate comparison of 2 courses of low MRD group and high MRD group:After 2courses,10 of 14 patients in the low MRD group achieved CR,the remission rate was71.42%,and 40 patients in the high MRD group 22 patients achieved CR,and the response rate was 55%.The exact probability calculation showed that P<0.001,the difference between the groups was statistically significant.After 4 courses of treatment,16 of the 21patients in the low MRD group achieved CR,the response rate was46.47%,and 13 of the33patients in the high MRD group achieved CR with a response rate of40.74%.The results of the?~2 test showed:P=0.001,the difference between the groups was statistically significant6.Effect of treatment regimen on MRD:After 2 and 4 courses of treatment in the bortezomib group,the low MRD rates were 21.42%and 53.57%,respectively.After 2and 4 courses in the non-bortezomib group,the low MRD rates were 15.78%and22.73%,respectively.?~2 test results show:P<0.001,the difference is statistically significant7.The OS and PFS of the patients with low MRD did not appear after 2 courses of induction therapy.The median OS of the high MRD group was 29 months,the median PFS was 22 months,and 4 were performed.After induction therapy,patients with low MRD had no OS and PFS.The median OS of the high MRD group was 27 months and the median PFS was 25 months.It can be concluded that patients in the low MRD group have a longer survival period regardless of the length of treatment.Analysis conclusion:1.According to this study,no matter which chemotherapy regimen is used,the induction therapy of 4 courses is easier to obtain low MRD,and the survival time of patients with low MRD is significantly prolonged after 4 courses of induction therapy.MRD can be used to assist in assessing a patient's OS and PFS,and can assist in the patient's disease status,assessment of efficacy,and predictive recurrence for better early intervention.2.By comparing the efficacy of bortezomib group and non-bortezomib group,patients with bortezomib group or non-bortezomib group were more likely to obtain low MRD after 4 courses of treatment,and the survival time was longer,resulting in MRD.More sensitive than traditional evaluation indicators.3.By comparing the efficacy of bortezomib group and non-bortezomib group,bortezomib group is more likely to obtain low MRD,which is of great significance for improving prognosis.